Effect of daily loperamide administration on gastrointestinal myoelectric activity

G. L. TELFORD, D. E. VARNER, L. L. McMANUS, S. WALGENBACH‐TELFORD, M. F. OTTERSON, R. E. CONDON, S. K. SARNA

Research output: Contribution to journalArticle

Abstract

The objective of this study was to determine the effect of daily administration of loperamide on gastrointestinal myoelectric activity. Six dogs were randomly administered three regimens–placebo, low dose loperamide (0.10–0.15 mg/kg/day, p.o.), and high dose loperamide (0.30–0.36 mg/kg/day, p.o.)–for one week each. Using surgically implanted bipolar electrodes, gastrointestinal myoelectric activity was recorded on at least 2 fed and 2 fasted experimental days for each regimen. In the fasted state, low dose loperamide decreased MMC cycle length, initiated intestinal amyogenesia in 40% of experiments, but did not induce vomiting. High‐dose loperamide in the fasted state did not change MMC cycle length, but induced vomiting in 50% of experiments and initiated intestinal amyogenesia in 43% of experiments. The rate of occurrence of the myoelectric carrelates of giant migrating contractions (GMCs) and retrograde giant contractions (RGCs) increased with loperamide administration at both doses, as did the rate of occurrence of fed state MMCs. We conclude that daily oral administration of loperamide results in: (1) a dose‐dependent effect on MMC cycle length; (2) intestinal amyogenesia; (3) an increase in frequency of vomiting at higher doses; and (4) an increase in incidence of GMCs and RGCs.

Original languageEnglish (US)
Pages (from-to)25-31
Number of pages7
JournalNeurogastroenterology and Motility
Volume4
Issue number1
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Loperamide
Vomiting
Implanted Electrodes
Oral Administration
Dogs
Incidence

Keywords

  • loperamide
  • motility
  • myoelectric activity
  • opioids
  • small intestine
  • stomach.

ASJC Scopus subject areas

  • Physiology
  • Endocrine and Autonomic Systems
  • Gastroenterology

Cite this

TELFORD, G. L., VARNER, D. E., McMANUS, L. L., WALGENBACH‐TELFORD, S., OTTERSON, M. F., CONDON, R. E., & SARNA, S. K. (1992). Effect of daily loperamide administration on gastrointestinal myoelectric activity. Neurogastroenterology and Motility, 4(1), 25-31. https://doi.org/10.1111/j.1365-2982.1992.tb00075.x

Effect of daily loperamide administration on gastrointestinal myoelectric activity. / TELFORD, G. L.; VARNER, D. E.; McMANUS, L. L.; WALGENBACH‐TELFORD, S.; OTTERSON, M. F.; CONDON, R. E.; SARNA, S. K.

In: Neurogastroenterology and Motility, Vol. 4, No. 1, 1992, p. 25-31.

Research output: Contribution to journalArticle

TELFORD, GL, VARNER, DE, McMANUS, LL, WALGENBACH‐TELFORD, S, OTTERSON, MF, CONDON, RE & SARNA, SK 1992, 'Effect of daily loperamide administration on gastrointestinal myoelectric activity', Neurogastroenterology and Motility, vol. 4, no. 1, pp. 25-31. https://doi.org/10.1111/j.1365-2982.1992.tb00075.x
TELFORD, G. L. ; VARNER, D. E. ; McMANUS, L. L. ; WALGENBACH‐TELFORD, S. ; OTTERSON, M. F. ; CONDON, R. E. ; SARNA, S. K. / Effect of daily loperamide administration on gastrointestinal myoelectric activity. In: Neurogastroenterology and Motility. 1992 ; Vol. 4, No. 1. pp. 25-31.
@article{3e83cb67bdcb406094c00960e7c545e9,
title = "Effect of daily loperamide administration on gastrointestinal myoelectric activity",
abstract = "The objective of this study was to determine the effect of daily administration of loperamide on gastrointestinal myoelectric activity. Six dogs were randomly administered three regimens–placebo, low dose loperamide (0.10–0.15 mg/kg/day, p.o.), and high dose loperamide (0.30–0.36 mg/kg/day, p.o.)–for one week each. Using surgically implanted bipolar electrodes, gastrointestinal myoelectric activity was recorded on at least 2 fed and 2 fasted experimental days for each regimen. In the fasted state, low dose loperamide decreased MMC cycle length, initiated intestinal amyogenesia in 40{\%} of experiments, but did not induce vomiting. High‐dose loperamide in the fasted state did not change MMC cycle length, but induced vomiting in 50{\%} of experiments and initiated intestinal amyogenesia in 43{\%} of experiments. The rate of occurrence of the myoelectric carrelates of giant migrating contractions (GMCs) and retrograde giant contractions (RGCs) increased with loperamide administration at both doses, as did the rate of occurrence of fed state MMCs. We conclude that daily oral administration of loperamide results in: (1) a dose‐dependent effect on MMC cycle length; (2) intestinal amyogenesia; (3) an increase in frequency of vomiting at higher doses; and (4) an increase in incidence of GMCs and RGCs.",
keywords = "loperamide, motility, myoelectric activity, opioids, small intestine, stomach.",
author = "TELFORD, {G. L.} and VARNER, {D. E.} and McMANUS, {L. L.} and S. WALGENBACH‐TELFORD and OTTERSON, {M. F.} and CONDON, {R. E.} and SARNA, {S. K.}",
year = "1992",
doi = "10.1111/j.1365-2982.1992.tb00075.x",
language = "English (US)",
volume = "4",
pages = "25--31",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effect of daily loperamide administration on gastrointestinal myoelectric activity

AU - TELFORD, G. L.

AU - VARNER, D. E.

AU - McMANUS, L. L.

AU - WALGENBACH‐TELFORD, S.

AU - OTTERSON, M. F.

AU - CONDON, R. E.

AU - SARNA, S. K.

PY - 1992

Y1 - 1992

N2 - The objective of this study was to determine the effect of daily administration of loperamide on gastrointestinal myoelectric activity. Six dogs were randomly administered three regimens–placebo, low dose loperamide (0.10–0.15 mg/kg/day, p.o.), and high dose loperamide (0.30–0.36 mg/kg/day, p.o.)–for one week each. Using surgically implanted bipolar electrodes, gastrointestinal myoelectric activity was recorded on at least 2 fed and 2 fasted experimental days for each regimen. In the fasted state, low dose loperamide decreased MMC cycle length, initiated intestinal amyogenesia in 40% of experiments, but did not induce vomiting. High‐dose loperamide in the fasted state did not change MMC cycle length, but induced vomiting in 50% of experiments and initiated intestinal amyogenesia in 43% of experiments. The rate of occurrence of the myoelectric carrelates of giant migrating contractions (GMCs) and retrograde giant contractions (RGCs) increased with loperamide administration at both doses, as did the rate of occurrence of fed state MMCs. We conclude that daily oral administration of loperamide results in: (1) a dose‐dependent effect on MMC cycle length; (2) intestinal amyogenesia; (3) an increase in frequency of vomiting at higher doses; and (4) an increase in incidence of GMCs and RGCs.

AB - The objective of this study was to determine the effect of daily administration of loperamide on gastrointestinal myoelectric activity. Six dogs were randomly administered three regimens–placebo, low dose loperamide (0.10–0.15 mg/kg/day, p.o.), and high dose loperamide (0.30–0.36 mg/kg/day, p.o.)–for one week each. Using surgically implanted bipolar electrodes, gastrointestinal myoelectric activity was recorded on at least 2 fed and 2 fasted experimental days for each regimen. In the fasted state, low dose loperamide decreased MMC cycle length, initiated intestinal amyogenesia in 40% of experiments, but did not induce vomiting. High‐dose loperamide in the fasted state did not change MMC cycle length, but induced vomiting in 50% of experiments and initiated intestinal amyogenesia in 43% of experiments. The rate of occurrence of the myoelectric carrelates of giant migrating contractions (GMCs) and retrograde giant contractions (RGCs) increased with loperamide administration at both doses, as did the rate of occurrence of fed state MMCs. We conclude that daily oral administration of loperamide results in: (1) a dose‐dependent effect on MMC cycle length; (2) intestinal amyogenesia; (3) an increase in frequency of vomiting at higher doses; and (4) an increase in incidence of GMCs and RGCs.

KW - loperamide

KW - motility

KW - myoelectric activity

KW - opioids

KW - small intestine

KW - stomach.

UR - http://www.scopus.com/inward/record.url?scp=84994913977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994913977&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.1992.tb00075.x

DO - 10.1111/j.1365-2982.1992.tb00075.x

M3 - Article

AN - SCOPUS:84994913977

VL - 4

SP - 25

EP - 31

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 1

ER -